APA (7th ed.) Citation

Arribas, A., Vultaggio, S., Andronache, A., Robusto, M., Fancelli, D., Cannas, E., . . . Bertoni, F. (2022). 304 (PB084) - Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. European Journal of Cancer, 174, S108. https://doi.org/10.1016/S0959-8049(22)01088-7

Chicago Style (17th ed.) Citation

Arribas, A., et al. "304 (PB084) - Pharmacological Screening Identified Promising Combination Partners in Marginal Zone Lymphoma Models with Secondary Resistance to BTK and PI3K Inhibitors." European Journal of Cancer 174 (2022): S108. https://doi.org/10.1016/S0959-8049(22)01088-7.

MLA (9th ed.) Citation

Arribas, A., et al. "304 (PB084) - Pharmacological Screening Identified Promising Combination Partners in Marginal Zone Lymphoma Models with Secondary Resistance to BTK and PI3K Inhibitors." European Journal of Cancer, vol. 174, 2022, p. S108, https://doi.org/10.1016/S0959-8049(22)01088-7.